Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2024
  • September
  • 17
  • Musk’s Neuralink gets FDA’s breakthrough device tag for ‘Blindsight’ implant

Musk’s Neuralink gets FDA’s breakthrough device tag for ‘Blindsight’ implant

Market Spectator September 17, 2024
2024-09-17T193520Z_2_LYNXMPEK8G0OD_RTROPTP_4_NEURALINK-MUSK-WIRES

(Reuters) -Elon Musk’s brain-chip startup Neuralink said on Tuesday its implant aimed at restoring vision received the U.S. Food and Drug Administration’s “breakthrough device” designation.

The FDA’s breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of experimental devices.

The experimental device, known as Blindsight, “will enable even those who have lost both eyes and their optic nerve to see,” Musk said in a post on X.

Neuralink is separately testing an implant designed to give paralyzed patients the ability to use digital devices by thinking alone, a prospect that could help people with spinal cord injuries.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)

Continue Reading

Previous: Microsoft approves new $60 billion share buyback program
Next: Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Categories

  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Uncategorized

Recent Posts

  • European drinks group skid after US surgeon general calls for cancer warnings
  • AI a productivity boost to banks but making money from it is a challenge
  • Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending
  • Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit
  • Stunning rally in Big Tech drives Nasdaq to 20,000

You may have missed

2025-01-03T141432Z_1_LYNXMPEL020G8_RTROPTP_4_PERNOD-RICARD-INDIA-RAJASTHAN
  • Business

European drinks group skid after US surgeon general calls for cancer warnings

Market Spectator January 3, 2025
2024-12-11T214504Z_1_LYNXMPEKBA10D_RTROPTP_4_REUTERS-NEXT-GOLDMAN-SACHS-CEO
  • Business

AI a productivity boost to banks but making money from it is a challenge

Market Spectator December 11, 2024
2024-12-11T212535Z_1_LYNXMPEKBA102_RTROPTP_4_ADOBE-RESULTS
  • Business

Adobe forecasts fiscal 2025 revenue below estimates on slower subscription spending

Market Spectator December 11, 2024
2024-12-11T213952Z_1_LYNXMPEKBA109_RTROPTP_4_TECH-ANTIRUST-MICROSOFT
  • Business

Microsoft expects $800 million impairment charge in Q2 2025 over General Motors’ Cruise exit

Market Spectator December 11, 2024
  • Home
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Contact Us
Copyright 2025 © All rights reserved | Market Spectator | marketspectator.com